ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Shalby earnings call we streamed: the live audio and our summary of what management said.
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech…
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech expansion and POSO revenue.
FY27: double-digit top-line growth, ETR ~45-50%, Gurgaon cash break-even near Q4 exit, lower net debt. No hard EBITDA or PAT numbers.
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.
Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.
Shalby Limited reports Q4 FY26 consolidated revenue growth of 9.4% YoY. The company is scaling its MedTech implant business and expanding hospital capacity through an asset-light O&M model.
Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.